Linvemastat

Overview

Linvemastat (Compound FC-4) is an orally active MMP-12 inhibitor ( IC 50 : < 10 nM) with high selectivity of MMP-1 , -2, -3, -7, -9, -10 and -14. Linvemastat significantly attenuates lung fibrosis in Bleomycin ( HY-108345 ) induced unilateral lung fibrosis mice model and potently reduces kidney damage, interstitial inflammation or fibrosis in kidney fibrosis model of unilateral ureteral occlusion. Linvemastat can be used for inflammatory diseases research, such as idiopathie pulmonary fibrosis (IPF), inflammatory bowel disease (IBD) and asthma.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > MMP

Product Information

• Catalog No.: HY-171804
• CAS No.: 2389060-50-6
• Molecular Formula: C20H17N3O4S
• Molecular Weight: 395.43
• Purity: 98.30%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 5 mg/mL (12.64 mM); Clear solution
• Availability: In-stock

Source

Original product source